Riverview Capital Advisers’s AstraZeneca AZN Stock Holding History

Riverview Capital Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,746	Closed	-$728K	–	92
2025 Q3	$728K	Sell	4,746 -1,250	-21%	-$189K	0.21%	59
2025 Q2	$838K	Sell	5,996 -483	-7%	-$67.7K	0.24%	62
2025 Q1	$952K	Hold	6,479	–	–	0.3%	58
2024 Q4	$849K	Hold	6,479	–	–	0.26%	59
2024 Q3	$1.01M	Hold	6,479	–	–	0.31%	52
2024 Q2	$1.01M	Hold	6,479	–	–	0.34%	53
2024 Q1	$878K	Hold	6,479	–	–	0.3%	53
2023 Q4	$873K	Buy	6,479 +19	+0.3%	+$2.47K	0.33%	50
2023 Q3	$875K	Hold	6,460	–	–	0.39%	57
2023 Q2	$925K	Hold	6,460	–	–	0.41%	53
2023 Q1	$897K	Hold	6,460	–	–	0.39%	57
2022 Q4	$876K	Hold	6,460	–	–	0.47%	48
2022 Q3	$709K	Hold	6,460	–	–	0.44%	53
2022 Q2	$854K	Hold	6,460	–	–	0.47%	51
2022 Q1	$857K	Hold	6,460	–	–	0.39%	54
2021 Q4	$753K	Buy	+6,460	New	+$760K	0.33%	57

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Riverview Capital Advisers's AZN Position: Q4 2025 in Review

Riverview Capital Advisers sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 4,746 shares — an estimated $728K sold.

Riverview Capital Advisers first reported a position in AZN in Q4 2021 and held it in 16 quarters. The position peaked at $1.01M in Q2 2024. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Riverview Capital Advisers reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Riverview Capital Advisers sold 4,746 AstraZeneca shares in Q4 2025, an estimated $728K.
Riverview Capital Advisers first reported a position in AstraZeneca in Q4 2021 and held it in 16 quarters.
Riverview Capital Advisers's AstraZeneca position peaked at $1.01M in Q2 2024.
1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Riverview Capital Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.